Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3371 - Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Prostate Cancer


Samanta Salvi


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


S. Salvi1, V. Conteduca2, V. Casadio1, P. Fici1, G. Gurioli1, F. Martignano1, U. Basso3, G. Fornarini4, C. Lolli2, G. Schepisi2, S. Testoni5, D. Calistri1, U. De Giorgi2

Author affiliations

  • 1 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 2 Department Of Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 3 Medical Oncology Unit 1, Department Of Clinical And Experimental Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 4 Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova/IT
  • 5 Unit Of Biostatistics And Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT


Abstract 3371


Cabazitaxel (CBZ) has been shown to improve overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients (pts) and to overcome resistance to docetaxel (DOC). Circulating tumor cells (CTCs) can be useful tool for precision medicine. CTCs expression profiling before CBZ treatment could establish novel predictive biomarkers.


We prospectively enrolled 28 pts with mCRPC treated with CBZ 25 mg/mq q21 after DOC and abiraterone or enzalutamide. CTCs enrichment was assessed with Adna Test EMT/STEM. Expression analyses of AKR1C3, AKT2, ALDH1, AR, ARV7, EPCAM, FOLH1, MDK, PARP, MRP1, PIK3CA, POU5F1, PSCA, TUBB3, VIM, ACT, HPRT1 were analyzed using real time PCR. CTCs positive pts were defined when at least one marker among AKT2, AR, AR-V7, EPCAM, FOLH1, PSCA, PIK3CA was expressed. Progressive disease was defined according to PCWG2 criteria. Main endpoint was the correlation between CTCs expression profiling and outcome.


Of these 28 pts, 18 (64%) had detectable CTCs before the starting of CBZ and 10 (36%) had undetectable CTCs. Detection of CTCs was associated with poor OS. However, no difference was observed for progression free survival (PFS). No correlation between CTCs assessment and PSA response rate was found. In addition, we subdivided pts according to median value of CTCs expression markers. Nine (50%) pts with ≥3 markers had a significant worse PFS compared to pts with


We prospectively confirmed a prognostic role for CTCs in mCRPC pts treated with CBZ and we also firstly showed the utility to characterize CTCs expression markers thanks to its potential predictive role. The identification of markers expressed on CTCs may also provide additional therapeutic targets. More details on the prognostic impact of these biomarkers and AR status and mutations are under analysis and will be presented at meeting.

Clinical trial identification


Legal entity responsible for the study

Ugo De Giorgi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.